/
/
EHA 2017: Elotuzumab Shows Long-Term Impact in 4-Year Study Follow-Up
EHA 2017: Elotuzumab Shows Long-Term Impact in 4-Year Study Follow-Up image
EHA 2017: Elotuzumab Shows Long-Term Impact in 4-Year Study Follow-Up
Posted Jul 06, 2017

Bristol-Myers Squibb presented four year updated data from their ELOQUENT-2 Trial, a trial enrolling 646 relapsed or refractory myeloma patients comparing elotuzumab/lenalidomide/dexamethasone vs. lenalidomide/dex. The triple combination therapy showed a 50% improvement in progression free survival (21%) compared to the len/dex doublet (14%). The Elo/len/dex (ELd) benefits were consistent at year 2, 3 and 4 follow-up. Patients with high risk myeloma showed a risk reduction of 36% and more than a doubling of progress free survival compared to the len/dex group. Patients who responsed to the triplet therapy (overall response rate) was 79% vs. 66% for the doublet. The triplet also had a median overall survival of 48 months vs. 40 months for len/dex. The survival shown on a Kaplan Meier survival curve was maintained over time in favor of Elo/Len/dex vs. Len/dex.

“These extended four-year follow-up data demonstrated that adding Empliciti to Ld yielded clinically relevant improvements and reductions in the risk of disease progression or death for patients with relapsed/refractory multiple myeloma, compared to Ld alone,” Meletios A. Dimopoulos, M.D., ELOQUENT-2 investigator and professor and chairman of the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens School of Medicine. “This data at four-year follow-up is particularly notable as it suggests the ability of this Immuno-Oncology agent to build a sustainable immune response in some patients with advanced multiple myeloma.” “The long-term efficacy data for Empliciti in patients with advanced multiple myeloma shows the combination of this Immuno-Oncology agent with standard lenalidomide/dexamethasone treatment can improve patient outcomes,” said Jonathan Leith, Ph.D., hematology development lead, Bristol-Myers Squibb. “These findings illustrate Bristol-Myers Squibb’s commitment to exploring how Immuno-Oncology agents might best help appropriate patients.”

To find all elotuzumab clinical trials, click here: Elotuzumab Clinical Trials

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811